Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8442139 | 0.89 | TET2 (0.32) | THRB | |
| SCHEMBL1783415 | 0.89 | ALDH1A1 (0.48) | ALDH1A1THRBTSHR | |
| Hydrochloric Acid SCHEMBL8440810 | 0.88 | ALDH1A1 (0.47) | ALDH1A1THRBTSHR | |
| Acrylic Acid Ethyl Ester SCHEMBL14841853 | 0.80 | ALDH1A1 (0.37) | ALDH1A1THRBTSHR | |
| SCHEMBL667786 | 0.78 | ALDH1A1 (0.62) | ALDH1A1THRBTSHR | |
| SCHEMBL534164 | 0.78 | THRB (0.34) | ALDH1A1THRBTSHR | |
| Chloromethane SCHEMBL5914760 | 0.77 | THRB (0.33) | ALDH1A1THRBTSHR | |
| Hydrochloric Acid SCHEMBL590980 | 0.77 | THRB (0.33) | ALDH1A1THRBTSHR | |
| SCHEMBL11101921 | 0.77 | ALDH1A1 (0.60) | ALDH1A1THRBTSHR | |
| Methacrylic Acid SCHEMBL6333244 | 0.77 | ALDH1A1 (0.60) | ALDH1A1THRBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061437-B1 | COMBINED PHARMACEUTICAL FORMULATION WITH CONTROLLED-RELEASE COMPRISING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AND HMG-COA REDUCTASE INHIBITORS | HANALL BIOPHARMA CO LTD (KR) | 2013-10-30 | — | — | EP | claimed |
| EP-2061437-A1 | COMBINED PHARMACEUTICAL FORMULATION WITH CONTROLLED-RELEASE COMPRISING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AND HMG-COA REDUCTASE INHIBITORS | Hanall Pharmaceutical Co., Ltd. (KR) | 2009-05-27 | — | — | EP | claimed |
| US-20080241240-A1 | COMBINED PHARMACEUTICAL FORMULATION WITH CONTROLLED-RELEASE COMPRISING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AND HMG-COA REDUCTASE INHIBITORS | HANALL PHARMACEUTICAL CO., LTD. (KR) | 2008-10-02 | — | — | US | claimed |
| WO-2008023869-A1 | COMBINED PHARMECEUTICAL FORMULATION WITH CONTROLLED-RELEASE COMPRISING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AND HMG-COA REDUCTASE INHIBITORS | HANALL PHARMACEUTICAL CO., LTD. (KR) | 2008-02-28 | — | — | WO | claimed |
| WO-2008023958-A1 | COMBINED PHARMACEUTICAL FORMULATION WITH CONTROLLED-RELEASE COMPRISING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AND HMG-COA REDUCTASE INHIBITORS | HANALL PHARMACEUTICAL CO., LTD. (KR) | 2008-02-28 | — | — | WO | claimed |
| US-20080050432-A1 | Combined Pharmaceutical Formulation with Controlled-Release Comprising Dihydropyridine Calcium Channel Blockers and HMG-COA Reductase Inhibitors | HANALL BIOPHARMA CO., LTD. (KR) | 2008-02-28 | — | — | US | claimed |
| EP-2109447-B1 | N, N- DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HANALL BIOPHARMA CO LTD (KR) | 2015-06-10 | — | — | EP | disclosed |
| EP-2061437-B1 | COMBINED PHARMACEUTICAL FORMULATION WITH CONTROLLED-RELEASE COMPRISING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AND HMG-COA REDUCTASE INHIBITORS | HANALL BIOPHARMA CO LTD (KR) | 2013-10-30 | — | — | EP | disclosed |
| US-8541474-B2 | N,N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same | HANALL BIOPHARMA CO., LTD. (KR) | 2013-09-24 | — | — | US | disclosed |
| US-20120010287-A1 | N, N -DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HANNAL BIOPHARMA CO., LTD. (KR) | 2012-01-12 | — | — | US | disclosed |
| US-8058312-B2 | N, N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same | HANALL BIOPHARMA CO., LTD. (KR) | 2011-11-15 | — | — | US | disclosed |
| US-20100087544-A1 | N, N -DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HANALL PHARMACEUTICAL COMPANY, LTD. (KR) | 2010-04-08 | — | — | US | disclosed |
| EP-2109447-A1 | N, N- DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Hanall Pharmaceutical Company LTD. (KR) | 2009-10-21 | — | — | EP | disclosed |
| EP-2061437-A1 | COMBINED PHARMACEUTICAL FORMULATION WITH CONTROLLED-RELEASE COMPRISING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AND HMG-COA REDUCTASE INHIBITORS | Hanall Pharmaceutical Co., Ltd. (KR) | 2009-05-27 | — | — | EP | disclosed |
| US-20080241240-A1 | COMBINED PHARMACEUTICAL FORMULATION WITH CONTROLLED-RELEASE COMPRISING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AND HMG-COA REDUCTASE INHIBITORS | HANALL PHARMACEUTICAL CO., LTD. (KR) | 2008-10-02 | — | — | US | disclosed |
| WO-2008093984-A1 | N, N- DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HANALL PHARMACEUTICAL COMPANY. LTD (KR) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008023869-A1 | COMBINED PHARMECEUTICAL FORMULATION WITH CONTROLLED-RELEASE COMPRISING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AND HMG-COA REDUCTASE INHIBITORS | HANALL PHARMACEUTICAL CO., LTD. (KR) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008023958-A1 | COMBINED PHARMACEUTICAL FORMULATION WITH CONTROLLED-RELEASE COMPRISING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AND HMG-COA REDUCTASE INHIBITORS | HANALL PHARMACEUTICAL CO., LTD. (KR) | 2008-02-28 | — | — | WO | disclosed |
| US-20080050432-A1 | Combined Pharmaceutical Formulation with Controlled-Release Comprising Dihydropyridine Calcium Channel Blockers and HMG-COA Reductase Inhibitors | HANALL BIOPHARMA CO., LTD. (KR) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087544-A1 | N, N -DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | TP53, TNNC1, TNNI3 | ALDH1A1 1197/4885THRB 3070/4885TSHR 3686/4885 |
| US-20120010287-A1 | N, N -DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | TP53, TNNC1, TNNI3 | ALDH1A1 1197/4885THRB 3070/4885TSHR 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.